Inactive Instrument

Syneos Health, Inc.

Equities

SYNH

US87166B1026

Biotechnology & Medical Research

Certain shares of INC Research Holdings, Inc.'s Class A Common Stock are subject to a Lock-Up Agreement Ending on 16-JAN-2016.

January 15, 2016

Certain shares of INC Research Holdings, Inc.'s Class A Common Stock are subject to a Lock-Up Agreement Ending on 16-JAN-2016. These shares will be under lockup for 45 days starting from 2-DEC-2015 to 16-JAN-2016.

Latest news about Syneos Health, Inc.

Syneos Health Names Colin Shannon CEO	23-10-03	MT
Syneos Health, Inc. Announces Chief Executive Officer Changes	23-10-03	CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P 400	23-09-29	CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P 400 Health Care	23-09-29	CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P Composite 1500	23-09-29	CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P TMI Index	23-09-29	CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P 1000	23-09-29	CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P Global BMI Index	23-09-29	CI
Syneos Health, Inc. Announces Management Changes	23-09-28	CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from NASDAQ Composite Index	23-09-28	CI
Syneos Health, Inc.'s Equity Buyback announced on June 1, 2022, has expired.	23-09-27	CI
Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C completed the acquisition of Syneos Health, Inc. from a group of shareholders.	23-09-27	CI
Civitas Resources to be Added to S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600	23-09-27	MT
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from NASDAQ Biotechnology Index	23-09-27	CI
Syneos Health Names Terttu Haring President, Clinical Sites & Patients	23-09-26	CI
Syneos Health, Oracle Collaborate to Speed Up Patient Recruitment for Clinical Studies	23-09-12	MT
Large LBO bond sales could prompt September US junk debt rush	23-09-07	RE
Syneos Health, Star Parent Plan $1.70 Billion Senior Secured Notes Offering	23-09-06	MT
European Commission Clears Joint Acquisition of Syneos Health	23-08-16	MT
Tranche Update on Syneos Health, Inc.'s Equity Buyback Plan announced on June 1, 2022.	23-08-09	CI
Syneos Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Syneos Health Gets Shareholder Approval for Acquisition Deal	23-08-02	MT
Click Therapeutics Launches Additional Randomized Clinical Study in Migraine, Conducted in Partnership with Syneos Health	23-08-02	CI
Syneos Health Appoints Hillary Bochniak as Chief Human Resources Officer	23-07-10	CI
Syneos Health, uMotif to Collaborate on Digital Platform for Clinical Trials	23-06-26	MT

Chart Syneos Health, Inc.

Duration

Period

More charts

Company Profile

Syneos Health, Inc. is a biopharmaceutical solutions company that utilizes outsourced clinical drug development and commercialization services. The Company operates through two business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The Clinical Solutions segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions (public relations, advertising, and medical communications), and consulting services. The Company's customers include small, mid-sized, and large companies in the biopharmaceutical, biotechnology, and medical device industries.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+17.72%	44.44B
IQVIA HOLDINGS INC.	-10.33%	37.99B
LONZA GROUP AG	+37.55%	37.75B
ALNYLAM PHARMACEUTICALS, INC.	+29.36%	30.78B
CELLTRION, INC.	-8.44%	27.38B
ICON PUBLIC LIMITED COMPANY	+12.45%	26.17B
UNITED THERAPEUTICS CORPORATION	+44.19%	14.15B
MEDPACE HOLDINGS, INC.	+31.93%	12.59B
BIO-TECHNE CORPORATION	-7.67%	11.28B

Other Biotechnology & Medical Research